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A B S T R A C T
Background
The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) for treating people with Plas-
modium falciparum malaria. Five combinations are currently recommended, all administered over three days. Artemisinin-naphtho-
quine is a new combination developed in China, which is being marketed as a one-day treatment. Although shorter treatment courses
may improve adherence, the WHO recommends at least three days of the short-acting artemisinin component to eliminate 90% P.
falciparum parasites in the bloodstream, before leaving the longer-acting partner drug to clear the remaining parasites.
Objectives
To evaluate the efficacy and safety of the artemisinin-naphthoquine combination for treating adults and children with uncomplicated
P. falciparum malaria.
Search methods
We searched theCochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL)
published in The Cochrane Library; MEDLINE; EMBASE; and LILACS up to January 2015. We also searched the metaRegister of
Controlled Trials (mRCT) using ’malaria’ and ’arte* OR dihydroarte*’ as search terms.
Selection criteria
Randomized controlled trials comparing artemisinin-naphthoquine combinations with establishedWHO-recommended ACTs for the
treatment of adults and children with uncomplicated malaria due to P. falciparum.
Data collection and analysis
Two review authors independently assessed trials for eligibility and risk of bias, and extracted data. We analysed primary outcomes in
line with the WHO ’Protocol for assessing and monitoring antimalarial drug efficacy’ and compared drugs using risk ratios (RR) and
95% confidence intervals (CI). Secondary outcomes were effects on gametocytes, haemoglobin, and adverse events. We assessed the
quality of evidence using the GRADE approach.
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Main results
Four trials, enrolling 740 adults and children, met the inclusion criteria. Artemisinin-naphthoquine was administered as a single dose
(two trials), as two doses given eight hours apart (one trial), and once daily for three days (one trial), and compared to three-day regimens
of established ACTs. Three additional small pharmaceutical company trials have been carried out. We have requested the data but have
not received a response from the company.
Artemisinin-naphthoquine versus artemether-lumefantrine
In three small trials from Benin, Côte d’Ivoire, and Papua New Guinea, both combinations had a very low incidence of treatment
failure at Day 28, and there were no differences demonstrated in PCR-unadjusted, or PCR-adjusted treatment failure (three trials, 487
participants, low quality evidence). Only the single study from Papua New Guinea followed participants up to Day 42, and the number
of treatment failures remained very low with both combinations (one trial, 186 participants, very low quality evidence).
Artemisinin-naphthoquine versus dihydroartemisinin-piperaquine
In a single small trial from Indonesia, treatment failure at Day 28 and Day 42 was very low in both groups with no differences
demonstrated (one trial, 144 participants, very low quality evidence).
Authors’ conclusions
The results of these few trials of artemisinin-naphthoquine are promising, but further trials frommultiple settings are required to reliably
demonstrate the relative efficacy and safety compared to established ACTs. Future trials should be adequately powered to demonstrate
non-inferiority, and regimens incorporating three days of the artemisinin component are probably preferable to the one-day regimens.
P L A I N L A N G U A G E S U M M A R Y
Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
This Cochrane Review summarises trials evaluating the effects of artemisinin-naphthoquine compared to other artemisinin-based
combination therapies (ACTs) recommended by theWorld Health Organization (WHO) for treating adults and children with uncom-
plicated P. falciparum malaria. After searching for relevant trials up to January 2015, we included four randomized controlled trials,
enrolling 740 adults and children.
What is uncomplicated malaria and how might artemisinin-naphthoquine work
Uncomplicated malaria is the mild form of malaria which usually causes a fever, with or without headache, tiredness, muscle pains,
abdominal pains, nausea, and vomiting. If left untreated, uncomplicated malaria can develop into severe malaria with kidney failure,
breathing difficulties, fitting, unconsciousness, and eventually death.
The WHO recommends ACT for treating people with P. falciparum malaria. Five combinations are currently recommended, all
administered over three days. Artemisinin-naphthoquine is a new combination developed in China, which is being marketed and
evaluated as one-day or three-day regimens.
What the research says
Artemisinin-naphthoquine versus artemether-lumefantrine
In three small trials fromBenin, Côte d’Ivoire, and PapuaNewGuinea, both artemisinin-naphthoquine and AL had a very low incidence
of treatment failure at Day 28 (low quality evidence), and in the trial from Papua New Guinea it remained low in both groups at Day
42 (very low quality evidence).
Artemisinin-naphthoquine versus dihydroartemisinin-piperaquine
In a single small study from Indonesia, treatment failure at Day 28 and Day 42 was very low with both artemisinin-naphthoquine and
DHA-P (very low quality evidence).
Conclusions
The results of these few trials of artemisinin-naphthoquine are promising, but larger trials from multiple settings are required to be
confident that artemisinin-naphthoquine is as effective and well tolerated as other antimalarials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Artemisinin-naphthoquine versus AL for treating uncomplicated P. falciparum malaria
Patient or population: Adults and children with uncomplicated P. falciparum malaria
Settings: Malaria endemic settings
Intervention: Artemisinin-naphthoquine (ART-NQ) (one or three-day course)
Comparison: Artemether-lumefantrine (AL) (three-day course)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
AL ART-NQ
Treatment failure at day 28 PCR-unadjusted RR 1.02
(0.24 to 4.37)
487
(3 trials)
⊕⊕©©
low1,2,3,4
1 per 100 1 per 100
(0 to 4)
PCR-adjusted RR 1.03
(0.15 to 7.07)
485
(3 trials)
⊕⊕©©
low1,2,3,4
0 per 100 0 per 100
(0 to 0)
Treatment failure at day 42 PCR-unadjusted RR 0.09
(0.00 to 1.59)
186
(1 trial)
⊕©©©
very low5,6,7
5 per 100 0 per 100
(0 to 8)
PCR-adjusted RR 0.33
(0.01 to 7.91)
186
(1 trial)
⊕©©©
very low5,6,7
1 per 100 0 per 100
(0 to 8)
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The basis for the assumed risk is the mean control group risk across included studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Two studies adequately concealed allocation to be at low risk of selection bias. In the other study the process
of randomization and allocation concealment was unclear.
2 No serious inconsistency: Statistical heterogeneity was low.
3 Downgraded by 1 for serious indirectness: Three studies have now evaluated this comparison, but only one used a three-day regimen
as recommended by the WHO. The three studies are from Benin, Côte d’Ivoire, and Papua New Guinea, and the level of treatment failure
with both artemisinin-naphthoquine and AL was very low, lower than seen in many trials of AL. Further studies from additional settings
are required before this result can be generalized to elsewhere.
4 Downgraded by 1 for serious imprecision: to demonstrate non-inferiority at 95% efficacy requires a sample size of 472. These trials
are individually significantly underpowered, and the number of events is too low to have full confidence in this result.
5 No serious risk of bias: This study adequately concealed allocation to be at low risk of selection bias.
6 Downgraded by 1 for serious indirectness: This single study is from Papua New Guinea. Further studies from additional settings are
required before this result can be generalized to elsewhere.
7 Downgraded by 2 for very serious imprecision: This trial is significantly underpowered to demonstrate non-inferiority.
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B A C K G R O U N D
Description of the condition
Malaria is a febrile illness caused by infection with the protozoan
parasitePlasmodium, and transmitted fromperson topersonby the
bite of infected mosquitoes. Five Plasmodium species are capable
of causing malaria in humans, of which Plasmodium falciparum is
the most common, responsible for over 90% of cases and almost
all of the malaria deaths worldwide (WHO 2012).
Uncomplicated malaria is the mild form of the disease, charac-
terised by fever with or without associated headache, tiredness,
muscle pains, abdominal pains, rigors, and nausea and vomit-
ing (WHO 2010a). If left untreated, uncomplicated malaria can
rapidly develop into severe, life threatening forms of the disease,
particularly in those without acquired immunity. Effective immu-
nity generally requires repeated infections over five to 10 years,
and is reduced during pregnancy. Consequently, in highly endemic
settings, as seen in many areas of rural sub-Saharan Africa, young
children and pregnant women are most at risk, while in settings
with low or seasonal transmission, all age groups can be equally at
risk (WHO 2010a).
P. falciparum has now developed resistance in many parts of the
world to most antimalarial drugs used as monotherapy (White
2004; WHO 2010b). Consequently, the World Health Organi-
zation (WHO) now recommends that P. falciparum malaria is al-
ways treated with a combination of two drugs that act at different
biochemical sites within the parasite (WHO 2010a). If a parasite
mutation producing drug resistance arises spontaneously during
treatment, the parasite should then be killed by the partner drug,
reducing or delaying the development of resistance, and increasing
the useful lifetime of the individual drugs (White 1996; White
1999).
Description of the intervention
Five artemisinin-based combination therapies (ACTs) are recom-
mended for the first-line treatment of uncomplicated malaria;
artemether-lumefantrine (AL), artesunate plus amodiaquine
(AS+AQ), artesunate plus mefloquine (AS+MQ), artesunate plus
sulphadoxine-pyrimethamine (AS+SP), and dihydroartemisinin-
piperaquine (DHA-P) (WHO 2010a). The artemisinin compo-
nents (artemether, artesunate, and dihydroartemisinin) are highly
effective schizonticides, and over three days of treatment rapidly
eliminate up to 90% of the blood stage asexual forms of P. falci-
parum. The partner drugs are longer acting and are used to clear
any residual infection (WHO 2010a). The combinations with
very long half-lives (AS+MQ and DHA-P), can provide a period
of post-treatment prophylaxis which may last for up to six weeks
(Sinclair 2009).
Artemisinin-naphthoquine is a new ACT developed by the
Academy of Military Medical Sciences Research Institute for
Microbial Epidemics in China (Wang 2004). Contrary to the
WHO recommendation for three-days of the artemisinin-deriva-
tive (WHO 2010a), this combination is being promoted for use
as either a single dose or two dose regimen administered over 24
hours (Hombhanje 2010). The rationale provided for the short-
ened regimen is to improve compliance with treatment.
Naphthoquine is a tetra-aminoquinoline that was developed in
China in the late 1980s. Whilst it was used as monotherapy
within China, it has never been widely used in other countries
(Hombhanje 2010). It is reported to be well absorbed orally, with
high bioavailability, and is excreted mainly via the kidneys (Wang
2004). Several pharmacokinetic studies are available but with con-
flicting estimates of the elimination half-life (Liu 2012). Early re-
ports were of a half-life of two to three days (Wang 2004), but
subsequent published studies found a mean half-life of 10.6 days
in healthy adult Chinese volunteers (Qu 2010), and 22.8 days in
children aged five to 12 years with malaria (Batty 2012). For com-
parison, the elimination half-lives of lumefantrine and mefloquine
in people with uncomplicated malaria are around three days, and
14 days respectively (Ezzet 2000; Karbwang 1990; WHO 2010a).
Artemisinin is a naturally occurring antimalarial compound which
canbe extracted from the plantArtemisia annua. Since its discovery
in the 1970s, product development has concentrated on its semi-
synthetic derivatives (artesunate, artemether, dihydroartemisinin)
due to the poor water solubility of artemisinin (Pawluk 2013;
Woodrow 2005).Once absorbed, these derivatives are rapidly con-
verted to the active metabolite dihydroartemisinin. Parasites resis-
tant to the artemisinin derivatives were first reported in Cambo-
dia in 2007 (Noedl 2008), and confirmed in Cambodia in 2008
(Dondorp 2009), and in Thailand in 2012 (Phyo 2012; WHO
2011).
Assessment of antimalarial drug efficacy
The WHO recommends that new antimalarials should have a
treatment failure rate of less than5%, and failure rateswith existing
first-line antimalarials higher than 10% should trigger a change in
treatment policy (WHO 2010a).
The late reappearance of P. falciparum parasites in the blood can be
due to failure of the drug to completely clear the original parasite
infection (a recrudescence) or due to a new infection, which is
especially common in areas of high transmission. A molecular
genotyping technique called polymerase chain reaction (PCR) can
be used in clinical trials to distinguish between recrudescence and
new infection, giving a clearer picture of the efficacy of the drug
and its post-treatment prophylactic effect (Cattamanchi 2003;
White 2002; WHO 2008).
The WHO recommends a minimum follow-up period of 28 days
for antimalarial efficacy trials, but longer periods of follow-up
may be required for antimalarials with long elimination half-lives
(Bloland 2003;White 2002). This is because treatment failure due
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to true recrudescence of malaria parasites may be delayed until
the drug concentration falls below the minimum concentration
required to inhibit parasite multiplication, which may be beyond
28 days. The WHO recommends 42 days follow-up for trials
involving lumefantrine and piperaquine and 63 days for trials of
mefloquine (WHO 2010a).
Why it is important to do this review
This Cochrane Review aims to systematically evaluate the avail-
able studies on the efficacy and safety of the artemisinin-naph-
thoquine combination for consideration by global and national
policy makers.
O B J E C T I V E S
To evaluate the efficacy and safety of the artemisinin-naphtho-
quine combination for treating adults and children with uncom-
plicated P. falciparum malaria.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs). We excluded quasi-RCTs.
Types of participants
Adults and children (including pregnant women and infants) with
symptomatic, microscopically confirmed, uncomplicated P. falci-
parum malaria.
Types of interventions
Intervention
A course of artemisinin-naphthoquine given as a single dose, or
multiple doses over one, two, or three days.
Control
A three-day course of a WHO-recommended ACT.
The specific ACTs included are: DHA-P; AS+MQ; AL (six doses);
AS+AQ; and AS+SP.
Types of outcome measures
Primary outcomes
Treatment failure at Days 28, 42, and 63; PCR-adjusted and PCR-
unadjusted.
Secondary outcomes
• Fever clearance.
• Parasite clearance.
• Gametocyte carriage at Day 7 or 14 (preference for Day 14
in data analysis).
• Gametocyte development (negative at baseline, and positive
at follow-up).
• Change in haemoglobin from baseline (minimum 28 day
follow-up).
Adverse events
• Deaths occurring during follow-up.
• Serious adverse events (life threatening, causing admission
to hospital, or discontinuation of treatment).
• Haematological and biochemical adverse effects (for
example, neutropenia, liver toxicity).
• Early vomiting.
• Other adverse events.
Search methods for identification of studies
Electronic searches
We searched the following databases up to 13 January 2015 us-
ing the search terms detailed in Appendix 1: Cochrane Infectious
Diseases Group Specialized Register; Cochrane Central Register
of Controlled Trials (CENTRAL) published in The Cochrane Li-
brary; MEDLINE; EMBASE; and LILACS.
Searching other resources
We contacted the manufacturer of artemisinin-naphthoquine in
October 2013 requesting further unpublished data.
We also checked the reference lists of all trials identified by the
database search.
Data collection and analysis
Selection of studies
Rachel Isba (RI) and Babalwa Zani (BZ) independently reviewed
the results of the literature search and obtained full-text copies
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of all potentially relevant trials. We checked each trial report for
evidence of multiple publications from the same data set. RI and
BZ then independently assessed each trial for inclusion in this re-
view using an eligibility form based on the inclusion criteria. We
resolved any disagreements through discussion or, where neces-
sary, by consultation with DS. If clarification was necessary, we
attempted to contact the trial authors for further information.
Data extraction and management
Two review authors (RI and BZ) independently extracted data us-
ing a pre-tested data extraction form. We extracted data on trial
characteristics including methods, participants, interventions, and
outcomes as well as data on dose and drug ratios of the combina-
tions.
We extracted the number of participants randomized and the num-
ber analysed in each treatment group for each outcome. We cal-
culated and report the loss to follow-up in each group.
For dichotomous outcomes, we recorded the number of partici-
pants experiencing the event and the number of participants in
each treatment group. For continuous outcomes, we extracted
the arithmetic means and standard deviations for each treatment
group together with the numbers of participants in each group. If
the data were reported using geometric means, we recorded this
information and extracted standard deviations on the log scale. If
medians were reported we extracted medians and ranges.
Primary outcome
Our primary analysis drew on the WHO protocol for assessing
and monitoring antimalarial drug efficacy (Bloland 2003). This
protocol has been used to guide most efficacy trials since its pub-
lication in 2003, even though it was designed to assess the level
of antimalarial resistance in the study area rather than for com-
parative trials. As a consequence, a high number of randomized
participants are excluded from the final efficacy outcome as losses
to follow-up, or voluntary or involuntary withdrawals. For this
reason we conducted a sensitivity analysis to restore the integrity
of the randomization process and test the robustness of the results
to this methodology. (For a summary of the methodology and
sensitivity analysis see Table 1).
PCR-unadjusted total failure
We calculated PCR-unadjusted total failure (P. falciparum) as the
sum of early treatment failures and late treatment failures (with-
out PCR adjustment). The denominator excluded participants for
whom an outcome was not available (for example, those who were
lost to follow-up, withdrew consent, took other antimalarials, or
failed to complete treatment) and those participants who were
found not to fulfil the inclusion criteria after randomization.
PCR-adjusted total failure
PCR-adjusted total failure (P. falciparum)was calculated as the sum
of early treatment failures plus late treatment failures due to PCR-
confirmed recrudescence.We treated participants with indetermi-
nate PCR results, missing PCR results, or PCR-confirmed new
infections as involuntary withdrawals and excluded them from the
calculation. The denominator excludes participants for whom an
outcome was not available (for example, those who were lost to
follow-up, withdrew consent, took other antimalarials, or failed to
complete treatment) and those participants who were found not
to fulfil the inclusion criteria after randomization.
These primary outcomes relate solely to failure due to P. falci-
parum. For both PCR-unadjusted and PCR-adjusted total failure,
participants infected with P. vivax during follow-up were retained
in the calculation if they were treated with chloroquine and con-
tinued in follow-up. As long as they did not go on to develop P.
falciparum parasitaemia they were classified as treatment successes.
We excluded from the calculation those participants who were in-
fected with P. vivax and were removed from the trial’s follow-up
at the time of P. vivax parasitaemia.
Assessment of risk of bias in included studies
Two review authors (RI and BZ) independently assessed the risk
of bias for each trial using The Cochrane Collaboration’s tool for
assessing the ’Risk of bias’ (Higgins 2011).We resolved any differ-
ences of opinion through discussionwith a third review author.We
followed the guidance to assess whether adequate steps were taken
to reduce the risk of bias across six domains: sequence generation;
allocation concealment; blinding (of participants, personnel, and
outcome assessors); incomplete outcome data; selective outcome
reporting; and other sources of bias.
For sequence generation and allocation concealment, we report
the methods used. For blinding, we describe who was blinded and
the blinding method. For incomplete outcome data, we report the
percentage and proportion lost to follow-up. For selective outcome
reporting, we state any discrepancies between the methods used
and the results, in terms of the outcomesmeasured or the outcomes
reported. For other biases, we describe any other trial features that
we think could affect the trial result (for example, if the trial was
stopped early).
We then categorized our judgements as ’low’, ’high’, or ’unclear’
risk of bias, and used this information to guide our interpretation
of the presented data. Where our judgement was unclear, we at-
tempted to contact the trial authors for clarification and resolved
any differences of opinion through discussion.
Measures of treatment effect
We analysed the data using Review Manager (RevMan). Dichoto-
mous data were combined and presented using risk ratios. For
continuous data summarized by arithmetic means and standard
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deviations, we combined data using mean differences. Risk ratios
and mean differences are accompanied by 95% CIs.
Unit of analysis issues
We did not encounter any unit of analysis issues.
Dealing with missing data
When trial reports were insufficient, unclear, or missing, we at-
tempted to contact the trial authors for additional information.
Assessment of heterogeneity
We assessed heterogeneity amongst trials by inspecting the forest
plots, applying the Chi² test with a 10% level of statistical signif-
icance, and also using the I² statistic with a value of 50% used to
denote moderate levels of heterogeneity.
Assessment of reporting biases
We planned to assess the possibility of publication bias by exam-
ining funnel plots for asymmetry, but there were too few trials to
make this meaningful.
Data synthesis
We gave the included trials identity codes which include the three-
letter international country code, and listed the trials in forest plots
in chronological order (by the final date of enrolment).
Treatments were compared directly using pair-wise comparisons.
For outcomes that were measured at different time points, we
stratified the analysis by the time point.
We performed meta-analysis where appropriate after assessment
and investigation of heterogeneity. In the first instance we used
a fixed-effect model, and used a random-effects model when the
Chi² test P value was less than 0.1 or the I² statistic greater than
50%.
Quality of evidence
We assessed the quality of evidence for each outcome measure us-
ing the GRADE approach. The quality rating across studies has
four levels: high, moderate, low, or very low. Randomized trials
are initially categorized as high quality but downgraded after as-
sessment of five criteria: risk of bias, consistency, directness, im-
precision, and publication bias (Guyatt 2008).
Subgroup analysis and investigation of heterogeneity
We planned to investigate potential sources of heterogeneity
through a series of analyses subgrouping the trials by: geographical
region, intensity of malaria transmission (low to moderate versus
high malaria transmission), known parasite resistance, allocation
concealment, participant age, and drug dose (comparing regimens
where there are significant variations in drug dose). However, there
were too few trials to make this meaningful.
Sensitivity analysis
We conducted a series of sensitivity analyses to investigate the
robustness of the methodology used in the primary analysis. We
aimed to restore the integrity of the randomization process by
adding excluded groups back into the analysis in a stepwise fashion
(see Table 1 for details).
R E S U L T S
Description of studies
Results of the search
We identified 15 articles as potentially relevant to this Cochrane
Review. Four RCTs met our inclusion criteria and we excluded 11
articles (see Figure 1).
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Figure 1. Study flow diagram.
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Included studies
The four trials randomized 740 participants with uncomplicated
P. falciparummalaria. Two trials (Laman 2014 PNG; Tjitra 2012
IDN) also included participants with P. vivax malaria or mixed
infections but we excluded these participants from this review.
The trials were conducted in Benin, Côte d’Ivoire, Papua New
Guinea, and Indonesia. The trial sites in Benin and Côte d’Ivoire
are described as having high transmission intensity and high levels
of resistance to chloroquine and SP (Kinde-Gazard 2012 BEN;
Toure 2009 CIV). In Indonesia, there were multiple trial sites
which are likely to have covered variable levels of transmission (al-
though this was not explicitly stated), and Indonesia has reported
resistance to chloroquine, quinine, and SP (Tjitra 2012 IDN). En-
demicity and resistance are not described in the study from Papua
New Guinea (Laman 2014 PNG).
Kinde-Gazard 2012 BEN recruited participants older than six
months, Toure 2009 CIV recruited children aged six months to
15 years, Laman 2014 PNG recruited children aged 6 months to
five years, and Tjitra 2012 IDN only recruited adults.
Three trials compared artemisinin-naphthoquine with a three-day
course of AL, but each trial used a different regimen of artemisinin-
naphthoquine: Kinde-Gazard 2012 BEN gave a single dose, Toure
2009 CIV gave two doses eight hours apart, and Laman 2014
PNG gave a daily dose for three days. It is unclear whether the
total dose is comparable across these three trials. Tjitra 2012 IDN
compared a single dose of artemisinin-naphthoquine with a three
day course of DHA-P.
Kinde-Gazard 2012 BEN and Toure 2009 CIV only report the
primary outcome at Day 28 post-treatment, while Laman 2014
PNG and Tjitra 2012 IDN report both Day 28 and Day 42.
Excluded studies
The excluded studies and reasons for their exclusion are given in
the ’Characteristics of excluded studies’ table.
Risk of bias in included studies
We summarised the ’Risk of bias’ assessments in Figure 2 and the
reasons for these judgements in the ’Characteristics of included
studies’ table.
10Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
11Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Allocation
Two trials adequately described random sequence generation and
allocation concealment to be considered at low risk of selectionbias
(Laman 2014 PNG; Toure 2009 CIV). In the other two trials the
description was unclear (Kinde-Gazard 2012 BEN; Tjitra 2012
IDN).
Blinding
Three trials adequately blinded the outcome assessors (laboratory
staff and study physicians) to be at low risk of detection bias. In
the remaining trial it was unclear whether outcome assessments
had been adequately blinded (Kinde-Gazard 2012 BEN).
Incomplete outcome data
All four trials were judged to be of low risk for attrition bias.
Selective reporting
We found no evidence of selective reporting.
Other potential sources of bias
The drugmanufacturer was involved in three trials (Kinde-Gazard
2012 BEN; Tjitra 2012 IDN; Toure 2009 CIV); however, it is
clearly stated in one of these that they had no involvement in the
design or analysis of the study (Toure 2009 CIV).
Effects of interventions
See: Summary of findings for the main comparison
Artemisinin-naphthoquine versus AL for treating uncomplicated
P. falciparum malaria; Summary of findings 2 Artemisinin-
naphthoquine versus DHA-P for treating uncomplicated P.
falciparum malaria
Comparison 1. Artemisinin-naphthoquine versus AL
Three trials compared artemisinin-naphthoquine with AL. These
trials recruited adults and children and administered artemisinin-
naphthoquine as a single dose (Kinde-Gazard 2012 BEN), as two
doses eight hours apart (Toure 2009 CIV), or once daily for three
days (Laman 2014 PNG). It is unclear whether the total dose is
comparable across these three trials.
Early clinical response to treatment
Two trials reported on fever clearance, with no significant differ-
ences between groups in the risk of remaining febrile after 24, 48,
or 72 hours (two trials, 321 participants, Analysis 1.1).
All three trials reported parasite clearance, with no significant dif-
ferences between groups at 24, 48 or 72 hours (three trials, 494
participants, Analysis 1.2).
Treatment failure
Across all three trials, only four participants had recurrent par-
asitaemia before Day 28, and only two were deemed to have a
recrudescence after PCR-adjustment. Consequently, there were
no statistically significant differences between groups (three trials,
487 participants, Analysis 1.3; Analysis 1.4). The trial from Papua
New Guinea continued follow-up until Day 42, by which time
there were five treatment failures with AL (one recrudescence and
four new infections) compared to none with artemisinin-naph-
thoquine (one trial, 186 participants, Analysis 1.5; Analysis 1.6).
Gametocytemia
Two trials reported on gametocyte carriage (Toure 2009 CIV and
Laman 2014 PNG). Gametocyte carriage was very low at baseline
in both groups in the trial from Côte d’Ivoire. Gametocyte car-
riage was higher at baseline in the trial from Papua New Guinea
and AL appeared to clear gametocytes quicker than artemisinin-
naphthoquine (Day 7 gametocyte carriage: RR 2.56, 95%CI 1.42
to 4.60, one trial, 197 participants, Analysis 1.7).
Anaemia
Toure 2009 CIV reported the number of participants who were
anaemic on Day 7 and found no significant difference between
the two groups (one trial, 120 participants, Analysis 1.8). Laman
2014 PNG presented mean haemoglobin for both groups graphi-
cally over 42 days follow-up. There was a small reduction in mean
haemoglobin in both groups during the first week which recov-
ered over the following five weeks. There was no difference be-
tween groups at any time point other than Day 42 when mean
haemoglobin was slightly lower with AL (P < 0.001, authors’ own
figures).
Adverse events
Across the three trials only one severe adverse event is de-
scribed, and this was considered non-drug-related; one child given
artemisinin-naphthoquine was admitted and treated for lobar
pneumonia (Laman 2014 PNG; see Table 2).
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All three trials conducted some form of clinical adverse eventmon-
itoring and no differences were reported in clinical symptoms after
treatment (three trials, 554 participants, Analysis 1.9).
One trial also conducted biochemical monitoring for adverse
events on Days 0, 3 and 7. No clinically important differences
were seen in tests of renal or liver function (Laman 2014 PNG).
The same trial also conducted ECG monitoring on Day 0, 2, 3
and 7 in a non-random sample of participants. After the second
dose on day two there were statistically significant differences in
the QT interval with 33.3% of those treated with artemisinin-
naphthoquine having a QTc > 460 msec compared with 3.7%
with AL (P value not reported). Differences were not statistically
significant at Day 3 or 7.
Comparison 2. Artemesinin-naphthoquine versus
DHA-P
One multi-centre trial in Indonesia compared artemisinin-naph-
thoquine with DHA-P (Tjitra 2012 IDN). This trial recruited
only adults and administered artemisinin-naphthoquine as a sin-
gle dose.
Early response to treatment
There was no significant differences in fever clearance, or parasite
clearance between the two groups (one trial, 149 participants,
Analysis 2.1; Analysis 2.2). All blood slides were clear of parasites
by Day 3.
Treatment failure
There were no PCR-unadjusted or PCR-adjusted treatment fail-
ures before Day 28 in either group (one trial, 143 participants,
Analysis 2.3; Analysis 2.4). By Day 42, two participants in each
group had recurrent parasitaemia, and after PCR-adjustment the
participants given artemisinin-naphthoquine were deemed to have
new infections, and those given DHA-P were deemed to have re-
crudescences (one trial, 143 participants; Analysis 2.5; Analysis
2.6).
Gametocytemia
OnDay 7, there was no significant differences in gametocytaemia
between the two trial arms (one trial, 150 participants, Analysis
2.7).
Anaemia
Not reported.
Adverse events
No serious adverse events were reported, and adverse events were
rare with no differences detected between the two treatments (one
trial, 152 participants, Analysis 2.8; see Table 2).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Artemisinin-naphthoquine versus DHA-P for treating uncomplicated P. falciparum malaria
Patient or population: Adults and children with uncomplicated P. falciparum malaria
Settings: Malaria endemic settings
Intervention: Artemisinin-naphthoquine (ART-NQ) (one-day course)
Comparison: Dihydroartemisinin-piperaquine (DHA-P) (three-day course)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
DHA-P ART-NQ
Treatment failure at day 28 PCR-unadjusted Not estimable 143
(1 trial)
⊕©©©
very low1,2,3
0 per 100 0 per 100
PCR-adjusted Not estimable 143
(1 trial)
⊕©©©
very low1,2,3
0 per 100 0 per 100
Treatment failure at day 42 PCR-unadjusted RR 0.91
(0.13 to 6.26)
143
(1 trial)
⊕©©©
very low1,2,3
3 per 100 3 per 100
(0 to 19)
PCR-adjusted RR 0.19
(0.01 to 3.82)
141
(1 trial)
⊕©©©
very low1,2,3
3 per 100 0 per 100
(0 to 11)
The basis for the assumed risk is the mean control group risk on the included studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: Although the description of the randomization procedure is vague, this trial is probably at low risk of selection
bias.
2 Downgraded by 1 for serious indirectness: This comparison has only been evaluated in a single setting. Further studies from additional
settings are required before this result can be generalized to elsewhere.
3 Downgraded by 2 for very serious imprecision: to demonstrate non-inferiority at 95% efficacy would require a sample size of 472. This
trial is significantly underpowered.
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D I S C U S S I O N
Summary of main results
In three small trials from Benin, Côte d’Ivoire, and Papua New
Guinea, both artemisinin-naphthoquine and AL had a very low
incidence of treatment failure at day 28 (low quality evidence).
In a single small study from Indonesia, treatment failure at day
28 and day 42 was very low with both artemisinin-naphthoquine
and DHA-P (very low quality evidence).
These trials were underpowered to detect clinically important dif-
ferences.
Overall completeness and applicability of
evidence
To date, there are only very limited data available on either the
efficacy or safety of artemisinin-naphthoquine and much larger
trials, from a wider variety of epidemiological settings will be re-
quired before this combination could be recommended. It is per-
haps helpful to note that DHA-P had been evaluated in 22 RCTs
enrolling almost 15,000 adults and children before it was formally
recommended by the WHO (Sinclair 2009), and artesunate plus
pyronaridine has been evaluated in three large multicentre trials
enrolling over 3000 participants but still requires further evidence
of efficacy and safety to have confidence in its effects (Bukirwa
2014).
Trials of around 500 participants are required to demonstrate
equivalent efficacy in a single setting (Table 3), and trials from
multiple settings are required to demonstrate that the findings can
be generalised to regions or continents, particularly for infectious
diseases such as malaria where infection patterns and drug resis-
tance vary widely. To rule out serious side-effects, particularly rare
ones, much larger patient numbers are required and this is usually
done through observational cohorts.
The trials included in this review suggest that this combination
has potential, but it is unclear whether the rationale of a shortened
24 hour regimen is justified. The current WHO recommendation
for three-day regimens is based on a trade-off between compliance
(enhanced by shorter regimens), efficacy (enhanced by longer reg-
imens), and the desire to reduce the risk of drug resistance de-
veloping (enhanced by combinations of two drugs acting via dif-
ferent mechanisms until parasitaemia is reduced to very low lev-
els). While compliance with the three-day regimens of established
ACTs has been poor in some studies, it is hard to understand why
shortening the regimen to 24 hours with artemisinin-naphtho-
quine would be any different to ensuring very poor compliance
with any other ACT. Consequently, it would probably be prefer-
able if future studies evaluated a three-day regimen.
Quality of the evidence
We assessed the quality of the evidence in this review using the
GRADE approach and presented the evidence in two ’Summary
of findings’ tables for efficacy (Summary of findings for the main
comparison; Summary of findings 2). We judge the evidence to be
of low or very low quality meaning that we have little confidence
in the findings of no statistically significant difference between the
tested ACTs. We downgraded the evidence by one level for serious
indirectness as artemisinin-naphthoquine has only been evaluated
in a limited number of settings and the findings are not easily
generalized, and by one or two levels for serious imprecision as the
trials are severely underpowered to detect differences.
Potential biases in the review process
None identified.
Agreements and disagreements with other
studies or reviews
We found two review articles authored by representatives of the
pharmaceutical developers (Hombhanje 2010;Wang 2004). Both
are narrative overviews rather than systematic reviews.Hombhanje
2010 includes the data from the three trials included here plus
some additional data from three unpublished trials. We have con-
tacted the pharmaceutical company requesting access to these data
but have not yet received it. Should these become available, we
will include them in the future updates of this review. Hombhanje
2010 concludes that “ARCO® demonstrated high level of effica-
ciousness and safety” but notes that further research is still neces-
sary. We are more conservative in our conclusions, and feel that
neither the efficacy nor the safety has yet been reliably established.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of these few trials of artemisinin-naphthoquine are
promising, but further trials frommultiple settings are required to
reliably demonstrate the relative efficacy and safety compared to
established ACTs.
Implications for research
Future trials should be adequately powered todemonstrate non-in-
feriority, and regimens incorporating three days of the artemisinin
component are probably preferable to the one-day regimens.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kinde-Gazard 2012 BEN
Methods Trial design: RCT
Follow-up: Patients were hospitalized for the first three days, and monitored clinically
and biochemically. Following discharge patients were seen on Day 7, 14, 21, and 28
with a malaria blood film at each visit
Adverse event monitoring: A symptom questionnaire, biochemistry (U and E, LFT),
and haematology were conducted at each visit
Participants Number: 174 participants randomized
Inclusion criteria: Age 6 months to 15 years, clinical signs of uncomplicated malaria,
temp > 37.5°C or history of fever in the last 24 hours, asexual P. falciparum density >
2000/µL, able to take oral medication, informed consent
Exclusion criteria: Signs of severe malaria, known hypersensitivity to study medications,
treatment with antimalarials within the past 7 days, positive pregnancy test
In addition the trial authors state that they planned to exclude the following groups
from the study: severe toxicity, abnormal biochemical tests, unsatisfactory therapeutic
response. However, no participants appear to have been excluded for these reasons
Interventions 1. Artemesinin-naphthoquine 125 mg/50 mg, fixed-dose combination (Arco, Kunming
Pharmaceutical Corporation, China):
• weight < 10 kg 1 tablet, single dose
• weight 10 to 15 kg 2 tablets, single dose
• weight 16 to 25 kg 4 tablets, single dose
• weight 26 to 35 kg 6 tablets, single dose
• weight > 35 kg 8 tablets, single dose
2. AL 20 mg/120 mg, fixed-dose combination (Coartem, Novartis SA, Switzerland):
• weight < 15 kg 1 tablet, twice a day for 3 days
• weight 15 to 24 kg 2 tablets, twice a day for 3 days
• weight 25 to 35 kg 3 tablets, twice a day for 3 days
• weight > 35 kg 4 tablets, twice a day for 3 days
Outcomes 1. PCR-adjusted and PCR-unadjusted treatment failure at Day 28
2. Haemoglobin
3. Adverse event
4. Fever clearance
5. Parasite clearance
Notes Country: Benin
Setting: Hospital
Transmission: High
Resistance: Chloroquine and SP
Dates: July to Oct 2008 and May to Sept 2009
Funding: None stated, however the randomization procedure was done by the manu-
facturer of artemisinin-naphthoquine
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Kinde-Gazard 2012 BEN (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “According to a randomization method”.
Allocation concealment (selection bias) Unclear risk None described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Described as “single blind”, however as the
drug regimens differed significantly blind-
ing of patients and personnel is unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Unclear risk Funding is unclear, but the pharmaceutical
company appear to be involved
Laman 2014 PNG
Methods Trial design: open-label, randomized controlled trial
Follow-up: Standardized assessment including axillary temp and blood film on Days 1,
2, 3, 7, 14, 28 and 42
Adverse event monitoring: Standardized assessment at each visit plus blood tests for full
blood count, hepatorenal function, and an electrocardiogram on Days 0, 3 and 7. An
additional electrocardiogram was performed 4 hours after Day 2 dose in those treated
with ART-NQ and in a convenience sample of 30 people treated with artemether-
lumefantrine
Participants Number: 198 participants with P. falciparum randomized.
Inclusion criteria: Age 6 months to 5 years, axillary temp > 37.5°C or history of fever in
the last 24 hours, asexual P. falciparum density > 1000/µL, or P. vivax > 250/µL.
Exclusion criteria: Signs of severe malaria, taken study drug in the previous 14 days,
known allergy to study medications, evidence of other infection or co-morbidity
Interventions 1. Artemesinin-naphthoquine; fixed-dose combination (Kunming Pharmaceutical Cor-
poration, China):
• Artemisinin 20 mg/kg plus naphthoquine 8 mg/kg daily for 3 days
• Dosed as 1 to 4 whole tablets per dose as per manufacturers instructions
2. AL: fixed-dose combination (Novartis Pharma, Switzerland):
• Artemether 1.7 mg/kg plus lumefantrine 10 mg/kg, twice daily for three days
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Laman 2014 PNG (Continued)
• Dosed as 1 to 3 whole tablets per dose (plus 250 mL of milk) as per
manufacturer’s instructions.
Direct observation of morning AL dose only
Outcomes 1. PCR-adjusted and PCR-unadjusted treatment failure at day 28 and day 42
2. Fever clearance
3. Parasite clearance
4. Gametocyte carriage
5. Haematological and biochemical adverse events
6. Clinical adverse events
Notes Country: Papua New Guinea
Setting: Health centres
Transmission: Not described
Resistance: Not described
Dates: March 2011 to April 2013
Funding: National Health andMedical Research Council, Australian Award PhD Schol-
arship, Esso-Highlands PNGIMR scholarship
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated block randomiza-
tion”.
Allocation concealment (selection bias) Low risk “Allocated treatments were concealed in
sealed numbered envelopes that were
opened in sequence by study medical or
nursing staff, and the specified treatment
was administered.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Treatments were not blinded, primarily
because the endpoints were based on ob-
jective clinical and parasitologic criteria”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All blood films were reexamined indepen-
dently by two skilled microscopists who
were blind to allocated treatment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk At day 28: 2/98 (2%) were lost to follow-
up with artemisinin-naphthoquine versus
6/100 (6%) with artemether-lumefantrine
At day 42: 4/98 (4%) were lost to follow-
up with artemisinin-naphthoquine versus
8/100 (8%) with artemether-lumefantrine
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
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Laman 2014 PNG (Continued)
Other bias Low risk “The funders had no role in study design,
data collection and analysis, decision to
publish, or preparation of the manuscript.
”
Tjitra 2012 IDN
Methods Trial design: A phase III, randomized, open label, multi-centre, comparative study
Follow-up: Limited physical exam on Days 1-2, 3, 7, 14, 12, 28, 35, and 42 and if
clinically indicated. ECG 2 to 4 hours after drug administration and on follow-up Days
7, 28, and 42. Thick and thin smears eight hourly in Days 0 to 2, then Days 3, 7, 14,
21, 28, 35, and 42. Haematology and blood chemistry at Days 3, 7, and 28. Blood spot
for PCR at Day 42 or failure. Urinalysis on Day 3. HCG for women on Days 0 and 28
Adverse event monitoring: “adverse events collected each time” and “Safety was assessed
through direct questioning, physical examinations, ECG abnormalities (prolongation
QT-interval), and significant change from baseline clinical laboratory parameters [17].
Adverse events were followed up until the event had resolved.”
Participants Number: 401 randomized (153 P. falciparum only, 90 mixed, 158 P. vivax only).
Inclusion criteria: adult, absence of severe malnutrition, axillary temperature > 37.5°C
or a history of fever within the preceding 24 hours, asexual P. falciparum density 1000 to
200,000/µL, P. vivax and other malaria density ≥ 250/µL, able to take oral treatment,
informed consent, uncomplicated P. falciparum or P. vivax mono-infection, or mixed
infection.
Exclusion criteria: severe vomiting, history or evidence of ’clinically systematic significant
disorders’, other febrile conditions, hypersensitivity or adverse reactions to antimalarials,
history of use of any other antimalarial agent within four weeks of the start of the trial
and confirmed by urine test, and pregnancy or lactating
Interventions 1. Artemesinin-naphthoquine, fixed-dose combination, 250 mg/100 mg tablets (Arco,
Kunming Pharmaceutical Corporation, China):
• 4 tablets as a single dose
2. DHA-P, fixed-dose combination, 40 mg/320 mg tablets (Duo-Cotecxin: Holey-Cotec
Pharmaceutical Co. Ltd, China):
• Daily doses of dihydroartemisinin 2 to 4 mg/kg and piperaquine 16 to 32 mg/kg
• weight ≤ 60 kg 3 tablets each day for 3 days
• weight > 60 kg 4 tablets each day for 3 days
All doses supervised.
Outcomes 1. ACPR at Day 42, PCR-adjusted and PCR-unadjusted
2. Gametocyte carriage
3. Adverse events
4. Fever clearance
5. Parasite clearance
Notes Country: Indonesia
Setting: Three Armed Forces hospitals in Jayapura (Marthen Indeys/Army, Soedibjo
Sardadi/Navy, and Bhayangkara/Police Hospitals) and one public hospital in Maumere
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Tjitra 2012 IDN (Continued)
(St. Gabriel Hospital)
Transmission: Not reported
Resistance: Widely reported resistance of P. falciparum to chloroquine, sulphadoxine-
pyrimethamine, and quinine
Dates: 2007 to 2008
Funding: Kunming Pharmaceutical Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Eligible subjects were blindly, randomly
assigned equally to one of the two treat-
ment groups using sealed envelopes”
Allocation concealment (selection bias) Low risk “Eligible subjects were blindly, randomly
assigned equally to one of the two treat-
ment groups using sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial described as “open label”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Microscopy results were blind cross-
checked by certified microscopists”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low losses to follow-up in both groups (3.
5% AS-N versus 5% DHA-P)
Selective reporting (reporting bias) Low risk All listed outcomes reported.
Other bias Unclear risk “We also thank to Kunming Pharma-
ceutical Corporation for funding the
artemisinin-naphthoquine trial.”
The role of the pharmaceutical company in
the design, conduct, and interpretation of
the trial is unclear
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Toure 2009 CIV
Methods Trial design: randomized single-blinded clinical trial
Follow-up: on Days 1, 2, 3, 7, 14, 21, and 28 (or any other day if they felt ill). Follow-
up evaluation was history and examination. Day 7 follow-up included full blood count
and liver profile. Blood spots collected for PCR on day of failure
Adverse event monitoring: “All observed adverse events were monitored actively and
passively from the time the participant has taken one dose of study treatment through
last visit, and were recorded on the Case Report Form (CRF) according to Good Clinical
Practice (GCP) and ICH guidelines.”
Participants Number: 125 randomized
Inclusion criteria:≥ six months old, P. falciparummonoinfection with parasitaemia level
of 2000 to 200,000 asexual parasites/µL, axillary temperature > 37.5°C or a history of
feverwithin the preceding24hours, nohistory of serious side effects to studymedications,
no evidence of concomitant febrile illness, provision of written informed consent by the
participant or parent/guardian
Exclusion criteria: symptoms or signs of severe malaria, or both, any “danger sign” (per-
sistent vomiting; inability to sit, stand, drink or breast feed), recent history of convulsions
or lethargy, or both, or otherwise impaired consciousness, haemoglobin concentration
≤ 6 mg/dL, serious underlying disease, or known allergy to the study drugs
“Participants were also excluded after randomization, if they repeatedly vomited their
first dose of study medications.”
“Participants were excluded after enrolment if any of the following occurred: (1) use of
antimalarial drugs outside of the study protocol; (2) parasitaemia in the presence of a
concomitant febrile illness; (3) withdrawal of consent; (4) loss to follow-up, (5) protocol
violation, or (6) death due to a non-malaria illness.”
Interventions 1. Artemesinin-naphthoquine, 125 mg/50 mg fixed-dose combination at 0, 8 hours
(Arco, Kunming Pharmaceutical Corporation, China):
• weight 6 to 10 kg ½ crushed tablet, 2 doses
• weight 10 to 15 kg 1 crushed tablet, 2 doses
• weight 15 to 25 kg 2 crushed tablets, 2 doses
• weight 25 to 35 kg 3 tablets, 2 doses
• weight ≥ 35 kg 4 tablets, 2 doses
2. AL fixed-dose combination (Coartem, Novartis SA, Switzerland):
• weight 5 to 15 kg 1 crushed tablet, twice a day for 3 days
• weight 15 to 25 kg 2 crushed tablets, twice a day for 3 days
• weight 25 to 35 kg 3 tablets, twice a day for 3 days
• weight ≥ 35 kg 4 tablets, twice a day for 3 days
Morning doses supervised and evening doses taken at home. “The empty sachets were
returned to study site as evidence of taking the drug”
Outcomes 1. PCR-adjusted and PCR-unadjusted treatment failure at day 28
2. Gametocyte carriage
3. Adverse events
4. Fever clearance
5. Parasite clearance
Notes Country: Côte d’Ivoire
Setting: Primary care centre in Anonkoua-kouté (crowded sub-urban area)
Transmission: “extremely high transmission intensity” and “holoendemic”
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Toure 2009 CIV (Continued)
Resistance: “Plasmodium falciparum resistance to affordable anti-malarial drugs (chloro-
quine and sulphadoxine-pyrimethamine) has reached high levels”
Dates: November 2006 to January 2007
Funding: Institut Pasteur, Kunming Pharmaecutical Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants recruited into the study were
allocated to two treatment groups using a
computer generated random list based on
a simple random selection procedure with-
out the use of blocking or stratification by
an off-site investigator.”
Allocation concealment (selection bias) Low risk “Sequentially numbered, sealed envelopes
containing the treatment group assign-
ments were prepared from the randomiza-
tion list. The study clinical investigators as-
signed treatment numbers sequentially and
a third party investigator who is an ap-
propriately qualified member of the study
site, allocated treatment by opening the
envelope corresponding to the treatment
number. The randomization codes were se-
cured in a locked cabinet accessible only
by the third party. Participants were en-
rolled by the study physicians, and treat-
ments were assigned and administered by
the third party.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants were not informed of their
treatment regimen.”
Comment: As the regimens are different
and no placebos were used participants
were essentially unblinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Only the third party was aware of treat-
ment assignments. All other study person-
nel, including the study physicians and lab-
oratory personnel involved in assessing out-
comes, were blinded to the treatment as-
signments.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant from each group didn’t
complete the study: 1 from AN lost to fol-
low-up and 1 from AL excluded
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Toure 2009 CIV (Continued)
Selective reporting (reporting bias) Low risk All listed outcomes reported.
Other bias Low risk No other sources of bias identified.
“Artemisinin/naphtho-
quine and Artemether/lumefantrine were
provided free of charge respectively byKun-
ming Pharmaceutical Corp. and Novartis S
A. The funders had no involvement in the
study design, data collection and its analy-
sis and interpretation, in the writing of pa-
per or in decision to submit it for publica-
tion”
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Batty 2012 Study 1 - no control group. Study 2 - not a relevant comparison. This study is a pharmacokinetic study comparing
a single dose of AS-N with two doses of AS-N given 24 hours apart
Benjamin 2012 Not a relevant comparison: this study compares a single dose of AS-N given with water versus a single dose of
AS-N given with milk versus two doses of AS-N
Guo 2003 Not a relevant comparison: this study compares naphthoquine monotherapy with artesunate monotherapy or
mefloquine monotherapy
Hombhanje 2009 Not a relevant comparison: this study compares a single dose of ART-NQwith a three day course of chloroquine
plus sulphadoxine-pyrimethamine
Liu 2012 A review article: discusses a pharmacokinetic study (Batty 2012).
Lui 2013 Not a relevant comparison: this study compares a three day course of ART-NQ with CQ plus primaquine for
treating P. vivax.
Meremikwu 2012 Not a relevant comparison: this study compares a single dose of ART-NQ versus a high single dose of ART-NQ
versus two dose of ART-NQ
Tun 2009 No control group: a single arm trial of a single dose ART-NQ in adults with uncomplicated P. falciparummalaria.
Wang 2002 No control group: single-arm trial of dihydroartemisinin combined with naphthoquine
Wang 2003 Not randomized.
Wang 2004 A review article.
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D A T A A N D A N A L Y S E S
Comparison 1. Artemisinin-naphthoquine versus AL
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever clearance 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Fever on day 1 2 321 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.48, 1.29]
1.2 Fever on day 2 2 319 Risk Ratio (M-H, Fixed, 95% CI) 2.73 [0.89, 8.43]
1.3 Fever on day 3 2 320 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.39, 3.52]
2 Parasite clearance 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Parasitaemia on day 1 3 494 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.86, 1.19]
2.2 Parasitaemia on day 2 3 494 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.43, 1.80]
2.3 Parasitaemia on day 3 3 494 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.18, 21.70]
3 PCR-unadjusted treatment
failure at day 28
3 487 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.24, 4.37]
4 PCR-adjusted treatment failure
at day 28
3 485 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.15, 7.07]
5 PCR-unadjusted treatment
failure at day 42
1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.59]
6 PCR-adjusted treatment failure
at day 42
1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.91]
7 Gametocyte carriage 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 At baseline 2 321 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.87, 1.80]
7.2 At day 7 2 320 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [1.42, 4.60]
7.3 At day 14 1 197 Risk Ratio (M-H, Fixed, 95% CI) 13.13 [1.75, 98.47]
8 Anaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 At baseline 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 On day 7 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Vomiting 2 380 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.39, 2.64]
9.2 Diarrhoea 2 380 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.30, 2.54]
9.3 Nausea 2 297 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.40, 2.25]
9.4 Abdominal pain 3 554 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.73, 2.45]
9.5 Anorexia 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.32, 27.60]
9.6 Dizziness 1 123 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [0.18, 21.14]
9.7 Headaches 1 257 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.61, 2.92]
9.8 Asthenia 1 123 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.38]
9.9 Trouble sleeping 1 257 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [0.19, 22.30]
9.10 Cough 1 257 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.81, 1.84]
9.11 Difficulty breathing 1 257 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.06, 16.19]
9.12 Pruritus 2 297 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.29, 7.34]
9.13 Skin rash 1 257 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.26, 4.00]
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Comparison 2. Artemisinin-naphthoquine versus DHA-P
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever clearance 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Fever on day 2 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Fever on day 3 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Parasite clearance 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Parasitaemia on day 1 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Parasitaemia on day 2 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Parasitaemia on day 3 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 PCR-unadjusted treatment
failure at day 28
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 PCR-adjusted treatment failure
at day 28
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 PCR-unadjusted treatment
failure at day 42
1 143 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.13, 6.26]
6 PCR-adjusted treatment failure
at day 42
1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.82]
7 Gametocyte carriage 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 At baseline 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 At day 7 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Vomiting 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Diarrhoea 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Nausea 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Anorexia 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.5 Dizziness 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.6 Asthenia 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.7 Abdominal pain 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.8 Pruritus 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.9 Cough 1 152 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [0.17, 19.95]
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Analysis 1.1. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 1 Fever clearance.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 1 Fever clearance
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fever on day 1
Laman 2014 PNG (1) 10/98 10/100 34.1 % 1.02 [ 0.44, 2.34 ]
Toure 2009 CIV (2) 13/62 19/61 65.9 % 0.67 [ 0.37, 1.24 ]
Subtotal (95% CI) 160 161 100.0 % 0.79 [ 0.48, 1.29 ]
Total events: 23 (AS-N), 29 (AL6)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Fever on day 2
Laman 2014 PNG 5/98 3/98 74.8 % 1.67 [ 0.41, 6.78 ]
Toure 2009 CIV 6/62 1/61 25.2 % 5.90 [ 0.73, 47.60 ]
Subtotal (95% CI) 160 159 100.0 % 2.73 [ 0.89, 8.43 ]
Total events: 11 (AS-N), 4 (AL6)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
3 Fever on day 3
Laman 2014 PNG 2/98 0/99 9.0 % 5.05 [ 0.25, 103.87 ]
Toure 2009 CIV 4/62 5/61 91.0 % 0.79 [ 0.22, 2.79 ]
Subtotal (95% CI) 160 160 100.0 % 1.17 [ 0.39, 3.52 ]
Total events: 6 (AS-N), 5 (AL6)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.28 (P = 0.78)
0.01 0.1 1 10 100
Favours AS-N Favours AL6
(1) Laman 2014: Artemisinin-naphthoquine once daily for three days versus Artemether-lumefantrine twice daily for three days
(2) Toure 2009: Two doses of Artemisinin-Naphthoquine given on the same day vs Artemether-lumefantrine twice daily for three days
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Analysis 1.2. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 2 Parasite clearance.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 2 Parasite clearance
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Parasitaemia on day 1
Kinde-Gazard 2012 BEN (1) 42/84 45/90 33.9 % 1.00 [ 0.74, 1.35 ]
Laman 2014 PNG (2) 68/98 66/99 51.2 % 1.04 [ 0.86, 1.26 ]
Toure 2009 CIV (3) 18/62 19/61 14.9 % 0.93 [ 0.54, 1.60 ]
Subtotal (95% CI) 244 250 100.0 % 1.01 [ 0.86, 1.19 ]
Total events: 128 (AS-N), 130 (AL6)
Heterogeneity: Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Parasitaemia on day 2
Kinde-Gazard 2012 BEN 0/84 3/90 23.6 % 0.15 [ 0.01, 2.92 ]
Laman 2014 PNG 12/98 11/99 76.4 % 1.10 [ 0.51, 2.38 ]
Toure 2009 CIV 0/62 0/61 Not estimable
Subtotal (95% CI) 244 250 100.0 % 0.88 [ 0.43, 1.80 ]
Total events: 12 (AS-N), 14 (AL6)
Heterogeneity: Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.35 (P = 0.72)
3 Parasitaemia on day 3
Kinde-Gazard 2012 BEN 0/84 0/90 Not estimable
Laman 2014 PNG 2/98 1/98 100.0 % 2.00 [ 0.18, 21.70 ]
Toure 2009 CIV 0/62 0/62 Not estimable
Subtotal (95% CI) 244 250 100.0 % 2.00 [ 0.18, 21.70 ]
Total events: 2 (AS-N), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
0.002 0.1 1 10 500
Favours AS-N Favours AL6
(1) Kinde-Gazard 2012: A single dose of Artemisinin-Naphthoquine vs Artemether-lumefantrine twice daily for three days
(2) Laman 2014: Artemisinin-naphthoquine once daily for three days versus Artemether-lumefantrine twice daily for three days
(3) Toure 2009: Two doses of Artemisinin-Naphthoquine given on the same day vs Artemether-lumefantrine twice daily for three days
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Analysis 1.3. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 3 PCR-unadjusted treatment
failure at day 28.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 3 PCR-unadjusted treatment failure at day 28
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kinde-Gazard 2012 BEN (1) 2/84 0/90 13.8 % 5.35 [ 0.26, 109.90 ]
Laman 2014 PNG (2) 0/96 1/94 43.2 % 0.33 [ 0.01, 7.91 ]
Toure 2009 CIV (3) 0/62 1/61 43.1 % 0.33 [ 0.01, 7.90 ]
Total (95% CI) 242 245 100.0 % 1.02 [ 0.24, 4.37 ]
Total events: 2 (AS-N), 2 (AL6)
Heterogeneity: Chi2 = 2.13, df = 2 (P = 0.34); I2 =6%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours AS-N Favours AL6
(1) Kinde-Gazard 2012: A single dose of Artemisinin-Naphthoquine vs Artemether-lumefantrine twice daily for three days
(2) Laman 2014: Artemisinin-naphthoquine once daily for three days versus Artemether-lumefantrine twice daily for three days
(3) Toure 2009: Two doses of Artemisinin-Naphthoquine given on the same day vs Artemether-lumefantrine twice daily for three days
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Analysis 1.4. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 4 PCR-adjusted treatment
failure at day 28.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 4 PCR-adjusted treatment failure at day 28
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kinde-Gazard 2012 BEN (1) 1/83 0/90 24.1 % 3.25 [ 0.13, 78.69 ]
Laman 2014 PNG (2) 0/96 1/94 75.9 % 0.33 [ 0.01, 7.91 ]
Toure 2009 CIV (3) 0/62 0/60 Not estimable
Total (95% CI) 241 244 100.0 % 1.03 [ 0.15, 7.07 ]
Total events: 1 (AS-N), 1 (AL6)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AS-N Favours AL6
(1) Kinde-Gazard 2012: A single dose of Artemisinin-Naphthoquine vs Artemether-lumefantrine twice daily for three days
(2) Laman 2014: Artemisinin-naphthoquine once daily for three days versus Artemether-lumefantrine twice daily for three days
(3) Toure 2009: Two doses of Artemisinin-Naphthoquine given on the same day vs Artemether-lumefantrine twice daily for three days
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Analysis 1.5. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 5 PCR-unadjusted treatment
failure at day 42.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 5 PCR-unadjusted treatment failure at day 42
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laman 2014 PNG (1) 0/94 5/92 100.0 % 0.09 [ 0.00, 1.59 ]
Total (95% CI) 94 92 100.0 % 0.09 [ 0.00, 1.59 ]
Total events: 0 (AS-N), 5 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AS-N Favours AL6
(1) Laman 2014: Artemisinin-naphthoquine once daily for three days versus Artemether-lumefantrine twice daily for three days
Analysis 1.6. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 6 PCR-adjusted treatment
failure at day 42.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 6 PCR-adjusted treatment failure at day 42
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laman 2014 PNG (1) 0/94 1/92 100.0 % 0.33 [ 0.01, 7.91 ]
Total (95% CI) 94 92 100.0 % 0.33 [ 0.01, 7.91 ]
Total events: 0 (AS-N), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AS-N Favours AL6
(1) Laman 2014: Artemisinin-naphthoquine once daily for three days versus Artemether-lumefantrine twice daily for three days
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Analysis 1.7. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 7 Gametocyte carriage.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 7 Gametocyte carriage
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At baseline
Laman 2014 PNG 40/98 33/100 94.2 % 1.24 [ 0.86, 1.79 ]
Toure 2009 CIV 3/62 2/61 5.8 % 1.48 [ 0.26, 8.53 ]
Subtotal (95% CI) 160 161 100.0 % 1.25 [ 0.87, 1.80 ]
Total events: 43 (AS-N), 35 (AL6)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.22)
2 At day 7
Laman 2014 PNG 31/98 12/99 92.2 % 2.61 [ 1.43, 4.78 ]
Toure 2009 CIV 2/62 1/61 7.8 % 1.97 [ 0.18, 21.14 ]
Subtotal (95% CI) 160 160 100.0 % 2.56 [ 1.42, 4.60 ]
Total events: 33 (AS-N), 13 (AL6)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.14 (P = 0.0017)
3 At day 14
Laman 2014 PNG 13/98 1/99 100.0 % 13.13 [ 1.75, 98.47 ]
Subtotal (95% CI) 98 99 100.0 % 13.13 [ 1.75, 98.47 ]
Total events: 13 (AS-N), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
0.01 0.1 1 10 100
Favours AS-N Favours AL6
35Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.8. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 8 Anaemia.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 8 Anaemia
Study or subgroup AS-N AL6 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At baseline
Toure 2009 CIV 29/60 23/60 1.26 [ 0.83, 1.91 ]
2 On day 7
Toure 2009 CIV 36/60 34/60 1.06 [ 0.78, 1.43 ]
0.01 0.1 1 10 100
Favours AS-N Favours AL6
Analysis 1.9. Comparison 1 Artemisinin-naphthoquine versus AL, Outcome 9 Adverse events.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 1 Artemisinin-naphthoquine versus AL
Outcome: 9 Adverse events
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vomiting
Laman 2014 PNG 7/127 5/130 62.0 % 1.43 [ 0.47, 4.40 ]
Toure 2009 CIV 1/62 3/61 38.0 % 0.33 [ 0.04, 3.07 ]
Subtotal (95% CI) 189 191 100.0 % 1.01 [ 0.39, 2.64 ]
Total events: 8 (AS-N), 8 (AL6)
Heterogeneity: Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.03 (P = 0.98)
2 Diarrhoea
Laman 2014 PNG 4/127 6/130 85.5 % 0.68 [ 0.20, 2.36 ]
Toure 2009 CIV 2/62 1/61 14.5 % 1.97 [ 0.18, 21.14 ]
0.001 0.01 0.1 1 10 100 1000
Favours AS-N Favours AL6
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(. . . Continued)
Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 189 191 100.0 % 0.87 [ 0.30, 2.54 ]
Total events: 6 (AS-N), 7 (AL6)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
3 Nausea
Kinde-Gazard 2012 BEN 8/84 7/90 69.1 % 1.22 [ 0.46, 3.23 ]
Toure 2009 CIV 1/62 3/61 30.9 % 0.33 [ 0.04, 3.07 ]
Subtotal (95% CI) 146 151 100.0 % 0.95 [ 0.40, 2.25 ]
Total events: 9 (AS-N), 10 (AL6)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.12 (P = 0.90)
4 Abdominal pain
Kinde-Gazard 2012 BEN 6/84 5/90 28.9 % 1.29 [ 0.41, 4.06 ]
Laman 2014 PNG 15/127 10/130 59.1 % 1.54 [ 0.72, 3.29 ]
Toure 2009 CIV 1/62 2/61 12.1 % 0.49 [ 0.05, 5.29 ]
Subtotal (95% CI) 273 281 100.0 % 1.34 [ 0.73, 2.45 ]
Total events: 22 (AS-N), 17 (AL6)
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
5 Anorexia
Toure 2009 CIV 3/62 1/61 100.0 % 2.95 [ 0.32, 27.60 ]
Subtotal (95% CI) 62 61 100.0 % 2.95 [ 0.32, 27.60 ]
Total events: 3 (AS-N), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
6 Dizziness
Toure 2009 CIV 2/62 1/61 100.0 % 1.97 [ 0.18, 21.14 ]
Subtotal (95% CI) 62 61 100.0 % 1.97 [ 0.18, 21.14 ]
Total events: 2 (AS-N), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
7 Headaches
Laman 2014 PNG 13/127 10/130 100.0 % 1.33 [ 0.61, 2.92 ]
Subtotal (95% CI) 127 130 100.0 % 1.33 [ 0.61, 2.92 ]
Total events: 13 (AS-N), 10 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
8 Asthenia
Toure 2009 CIV 1/62 1/61 100.0 % 0.98 [ 0.06, 15.38 ]
Subtotal (95% CI) 62 61 100.0 % 0.98 [ 0.06, 15.38 ]
Total events: 1 (AS-N), 1 (AL6)
0.001 0.01 0.1 1 10 100 1000
Favours AS-N Favours AL6
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Study or subgroup AS-N AL6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
9 Trouble sleeping
Laman 2014 PNG 2/127 1/130 100.0 % 2.05 [ 0.19, 22.30 ]
Subtotal (95% CI) 127 130 100.0 % 2.05 [ 0.19, 22.30 ]
Total events: 2 (AS-N), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
10 Cough
Laman 2014 PNG 37/127 31/130 100.0 % 1.22 [ 0.81, 1.84 ]
Subtotal (95% CI) 127 130 100.0 % 1.22 [ 0.81, 1.84 ]
Total events: 37 (AS-N), 31 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
11 Difficulty breathing
Laman 2014 PNG 1/127 1/130 100.0 % 1.02 [ 0.06, 16.19 ]
Subtotal (95% CI) 127 130 100.0 % 1.02 [ 0.06, 16.19 ]
Total events: 1 (AS-N), 1 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
12 Pruritus
Kinde-Gazard 2012 BEN 2/84 2/90 79.3 % 1.07 [ 0.15, 7.44 ]
Toure 2009 CIV 1/62 0/61 20.7 % 2.95 [ 0.12, 71.09 ]
Subtotal (95% CI) 146 151 100.0 % 1.46 [ 0.29, 7.34 ]
Total events: 3 (AS-N), 2 (AL6)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
13 Skin rash
Laman 2014 PNG 4/127 4/130 100.0 % 1.02 [ 0.26, 4.00 ]
Subtotal (95% CI) 127 130 100.0 % 1.02 [ 0.26, 4.00 ]
Total events: 4 (AS-N), 4 (AL6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Chi2 = 2.07, df = 12 (P = 1.00), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours AS-N Favours AL6
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Analysis 2.1. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 1 Fever clearance.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 1 Fever clearance
Study or subgroup AS-N DHA-P Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fever on day 2
Tjitra 2012 IDN 0/67 0/61 Not estimable
2 Fever on day 3
Tjitra 2012 IDN 0/56 1/50 0.30 [ 0.01, 7.16 ]
0.01 0.1 1 10 100
Favours AS-N Favours DHA-P
Analysis 2.2. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 2 Parasite clearance.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 2 Parasite clearance
Study or subgroup AS-N DHA-P Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Parasitaemia on day 1
Tjitra 2012 IDN 43/77 39/72 1.03 [ 0.77, 1.38 ]
2 Parasitaemia on day 2
Tjitra 2012 IDN 3/78 0/70 6.29 [ 0.33, 119.69 ]
3 Parasitaemia on day 3
Tjitra 2012 IDN 0/76 0/68 Not estimable
0.005 0.1 1 10 200
Favours AS-N Favours DHA-P
39Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.3. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 3 PCR-unadjusted
treatment failure at day 28.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 3 PCR-unadjusted treatment failure at day 28
Study or subgroup AS-N DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tjitra 2012 IDN 0/75 0/68 Not estimable
Total (95% CI) 75 68 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours AS-N Favours DHA-P
Analysis 2.4. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 4 PCR-adjusted treatment
failure at day 28.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 4 PCR-adjusted treatment failure at day 28
Study or subgroup AS-N DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tjitra 2012 IDN 0/75 0/68 Not estimable
Total (95% CI) 75 68 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AS-N Favours DHA-P
40Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.5. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 5 PCR-unadjusted
treatment failure at day 42.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 5 PCR-unadjusted treatment failure at day 42
Study or subgroup AS-N DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tjitra 2012 IDN 2/75 2/68 100.0 % 0.91 [ 0.13, 6.26 ]
Total (95% CI) 75 68 100.0 % 0.91 [ 0.13, 6.26 ]
Total events: 2 (AS-N), 2 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AS-N Favours DHA-P
Analysis 2.6. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 6 PCR-adjusted treatment
failure at day 42.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 6 PCR-adjusted treatment failure at day 42
Study or subgroup AS-N DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tjitra 2012 IDN 0/73 2/68 100.0 % 0.19 [ 0.01, 3.82 ]
Total (95% CI) 73 68 100.0 % 0.19 [ 0.01, 3.82 ]
Total events: 0 (AS-N), 2 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours AS-N Favours DHA-P
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Analysis 2.7. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 7 Gametocyte carriage.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 7 Gametocyte carriage
Study or subgroup AS-N DHA-P Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At baseline
Tjitra 2012 IDN 21/79 18/74 1.09 [ 0.63, 1.88 ]
2 At day 7
Tjitra 2012 IDN 9/78 6/72 1.38 [ 0.52, 3.70 ]
0.01 0.1 1 10 100
Favours AS-N Favours DHA-P
Analysis 2.8. Comparison 2 Artemisinin-naphthoquine versus DHA-P, Outcome 8 Adverse events.
Review: Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Comparison: 2 Artemisinin-naphthoquine versus DHA-P
Outcome: 8 Adverse events
Study or subgroup AS-N DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vomiting
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Diarrhoea
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours AS-N Favours DHA-P
(Continued . . . )
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(. . . Continued)
Study or subgroup AS-N DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: not applicable
3 Nausea
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Anorexia
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Dizziness
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Asthenia
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Abdominal pain
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Pruritus
Tjitra 2012 IDN 0/79 0/73 Not estimable
Subtotal (95% CI) 79 73 Not estimable
Total events: 0 (AS-N), 0 (DHA-P)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Cough
Tjitra 2012 IDN 2/79 1/73 100.0 % 1.85 [ 0.17, 19.95 ]
Subtotal (95% CI) 79 73 100.0 % 1.85 [ 0.17, 19.95 ]
Total events: 2 (AS-N), 1 (DHA-P)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours AS-N Favours DHA-P
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(. . . Continued)
Study or subgroup AS-N DHA-P Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AS-N Favours DHA-P
A D D I T I O N A L T A B L E S
Table 1. Primary outcome measure (Total failure)
Analysis Participants PCRb-unadjusted PCR-adjusted
Numerator Denominator Numerator Denominator
Primary analysisa Exclusions after en-
rolment
Excludedc Excluded Excluded Excluded
Missing or indeter-
minate PCR
Included as failures Included Excluded Excluded
New infections Included as failures Included Excluded Excluded
Sensitivity analysis 1
d
As ’Primary analysis’
except: missing or
indeterminate PCR
- - Included as failures Included
Sensitivity analysis 2
e
As ’Sensitivity anal-
ysis 1’ except: new
infections
- - Included as successes Included
Sensitivity analysis 3
f
As ’Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as failures Included Included as failures Included
Sensitivity analysis 4
g
As ’Sensitivity anal-
ysis 2’ except: ex-
clusions after enrol-
ment
Included as
successes
Included Included as successes Included
a Note: participants who were found to not satisfy the inclusion criteria after randomization are removed from all calculations.
b PCR: polymerase chain reaction.
c ’Excluded’ means removed from the calculation.
d To re-classify all indeterminate or missing PCR results as treatment failures in the PCR-adjusted analysis.
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e To re-classify all PCR-confirmed new infections as treatment successes in the PCR-adjusted analysis. (This analysis may overestimate
efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may
have gone on to develop a recrudescence after the new infection.)
f To re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment failures. For PCR-unadjusted total failure this represents a true worse-case scenario.
g To re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment successes.
Table 2. Serious adverse events
Comparison Trial ID Description of severe adverse events provided by publication
ART-NQ versus AL Kinde-Gazard 2012 BEN Not mentioned.
Toure 2009 CIV “No severe alterations in renal, haematologic or hepatic function were ob-
served with any of the drug combinations under study.”
Other adverse events are described as mild.
Laman 2014 PNG “The only severe adverse event was considered non-drug related. A 48
month old child allocated to artemisinin-naphthoquine was hospitalized
and treated successfully for lobar pneumonia.”
ART-NQ versus DHA-P Tjitra 2012 IDN “There were no serious adverse events reported in malaria subjects treated
with ART-NQ and DHA-P during the study”
Table 3. Optimal information size calculations
Outcome Hypothesis Example Power α error Proportion in
control group
Proportion in
intervention
group
Maximum
risk difference
Total sample
size
PCR-ad-
justed treat-
ment
failure
Superiority Assuming a
10% failure
rate with the
old drug and
that a new
drug should
be at least
95% effec-
tive
80% 5% 0.10 0.05 - 864
Non-
inferiority
As-
suming that
both drugs
are 95% ef-
fective and
that there is
no more
than a 5%
80% 5% 0.05 0.05 0.05 472
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Table 3. Optimal information size calculations (Continued)
difference in
efficacy
We performed calculations with http://www.sealedenvelope.com
A P P E N D I C E S
Appendix 1. Detailed search strategy
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACS
1 malaria Malaria ti, ab, Mesh Malaria ti, ab, Mesh Malaria ti, ab, Emtree malaria
2 arte* arte* ti, ab arte* ti, ab arte* Arte$
3 dihydroarte* dihydroarte* ti, ab dihydroarte* ti, ab dihydroarte* Dihydroarte$
4 Coartem* Coartem* ti, ab Coartem* ti, ab Coartem$ Coartem$
5 lumefantrine Lumefantrine ti, ab Lumefantrine ti, ab lumefantrine lumefantrine
6 2 or 3 or 4 or 5 2 or 3 or 4 or 5 2 or 3 or 4 or 5 2 or 3 or 4 or 5 2 or 3 or 4 or 5
7 Naphthoquin* Naphthoquin* ti, ab Naphthoquin* ti, ab Naphthoquin* ti, ab Naphthoquin$
8 1 and 6 and 7 Naphtho-
quinones[Mesh]
Naphtho-
quinones[Mesh]
Naphthoquinone
[Emtree]
1 and 6 and 7
9 7 or 8 7 or 8 7 or 8
10 1 and 6 and 9 1 and 6 and 9 1 and 6 and 9
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2011).
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Appendix 2. Adverse event monitoring
Trial ID Sample Size Blinding Clinical symp-
toms monitoring
Biochemistry Haematological Electrocardio-
gram
Laman 2014
PNG
198 Open label Standard-
ized assessment on
days 1, 2, 3, 7, 14,
28 and 42.
Hepatorenal func-
tion on days 0, 3
and 7.
Full blood count,
on days 0, 3 and 7.
Electrocardiogram
on days 0, 3 and 7.
An additional elec-
trocardiogram was
performed 4 hours
after day 2 dose in
those treated with
ART-NQ and in
a convenience sam-
ple of 30 peo-
ple treated with
artemether-
lumefantrine
Tjitra 2012 IDN 243 Open label Lim-
ited physical exam
on days 1 to 2, 3, 7,
14, 12, 28, 35, and
42 and if clinically
indicated
Blood chemistry at
days 3, 7, and 28.
Haematology at
days 3, 7, and 28.
ECG 2 to 4 hours
after drug adminis-
tration and on fol-
low-up days 7, 28,
and 42
Kinde-Gazard
2012 BEN
174 Single Patients were hos-
pitalized for the
first three days, and
monitored
clinically; follow-
ing discharge pa-
tients were seen on
days 7, 14, 21,
28 and a symp-
tom questionnaire
was conducted at
each visit
Biochemistry (U
and E, LFT) whilst
patients were hos-
pitalized for
the first three days;
then following dis-
charge on days 7,
14, 21, 28
Haema-
tology whilst pa-
tients were hospi-
talized for
the first three days;
then following dis-
charge on days 7,
14, 21, 28
-
Toure 2009 CIV 125 Single Follow-up: on days
1, 2, 3, 7, 14,
21, and 28 (or any
other day if they
felt ill). Follow-up
evaluation was his-
tory and examina-
tion. “All observed
adverse events were
monitored actively
and passively from
Day 7 follow-up
included liver pro-
file.
Day 7 follow-up
included liver pro-
file.
-
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(Continued)
the time the par-
ticipant has taken
one dose of study
treatment through
last visit, and were
recorded on the
Case Report Form
(CRF) accord-
ing to Good Clini-
cal Practice (GCP)
and ICH guide-
lines.”
C O N T R I B U T I O N S O F A U T H O R S
DS and BZ contributed to the development of the standard protocol as used in Sinclair 2009. BZ drafted the background. RI and MG
reviewed the reference list, extracted data, and entered it into Review Manager (RevMan). RI, MG, and DS conducted the analyses,
constructed ’Summary of findings’ tables, and evaluated the quality of evidence using the GRADE approach. RI wrote the first draft
and all authors reviewed and contributed to the final draft.
D E C L A R A T I O N S O F I N T E R E S T
The review authors have no conflicting interests.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development (DFID), UK.
48Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
